로딩 중…
지수 로딩 중…
Xcell Therapeutics
373110· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩1,300-2.55%
2026-06-19
Price Chart
Xcell Therapeutics-53.62%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 22.48B KRW |
| Revenue | 3.31B KRW |
| Net Income | -11.31B KRW |
| Total Assets | 14.92B KRW |
| Net Assets | 6.54B KRW |
| Employees | 68 |
| Value | |
| P/B | 3.44x |
| P/S | 6.80x |
| FCF Yield | -46.12% |
| Profitability | |
| ROE | -172.83% |
| ROA | -75.77% |
| Op. Margin | -328.22% |
| Revenue Growth | 0.76% |
| Financial Health | |
| Debt Ratio | 228.08% |
| Total Debt | 4.60B KRW |
| FCF | -10.37B KRW |
| Cash | 6.02B KRW |
| Current Ratio | 1.88x |
| Performance | |
| 1Y Return | -53.62% |
| 1M Return | 5.78% |
| From 52W High | -64.20% |
| 1Y MDD | -64.81% |
| Trading | |
| Volume | 172,865 shares |
| Foreign Own. | 4.60% |
| Per Share | |
| EPS | -784 KRW |
| BPS | 378 KRW |
Company Info
Excell Therapeutics, established in 2015 and listed on KOSDAQ in 2024 as a technology growth company, specializes in cell culture media. The company primarily manufactures and supplies chemically defined media, 'CellCor', which excludes animal and human-derived substances crucial for the cell and gene therapy industry, from its GMP production facilities. It has developed the cell-customized medium development platform technology XPorT and is expanding its business into advanced biopharmaceuticals. Excell Therapeutics is headquartered in Gangnam-gu, Seoul.